HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Irisin Suppresses Nicotine-Mediated Atherosclerosis by Attenuating Endothelial Cell Migration, Proliferation, Cell Cycle Arrest, and Cell Senescence.

Abstract
Atherosclerotic disease has become the major cause of death worldwide. Smoking, as a widespread independent risk factor, further strengthens the health burden of atherosclerosis. Irisin is a cytokine that increases after physical activity and shows an atheroprotective effect, while its specific mechanism in the process of atherosclerosis is little known. The reversal effect of irisin on intimal thickening induced by smoking-mediated atherosclerosis was identified in Apoe -/- mice through the integrin αVβ5 receptor. Endothelial cells treated with nicotine and irisin were further subjected to RNA-seq for further illustrating the potential mechanism of irisin in atherosclerosis, as well as the wound healing assays, CCK-8 assays, β-gal staining and cell cycle determination to confirm phenotypic alterations. Endothelial differential expressed gene enrichment showed focal adhesion for migration and proliferation, as well as the P53 signaling pathway for cell senescence and cell cycle control. Irisin exerts antagonistic effects on nicotine-mediated migration and proliferation via the integrin αVβ5/PI3K pathway. In addition, irisin inhibits nicotine-mediated endothelial senescence and cell cycle arrest in G0/G1 phase via P53/P21 pathway. This study further illustrates the molecular mechanism of irisin in atherosclerosis and stresses its potential as an anti-atherosclerotic therapy.
AuthorsJunye Chen, Kang Li, Jiang Shao, Zhichao Lai, Ran Gao, Chaonan Wang, Xitao Song, Wenjun Guo, Xiaoxi Yu, Fenghe Du, Zhan Zhu, Jiaxian Wang, Jiangyu Ma, Leyin Xu, Yan Zhou, Jianghao Liu, Keqiang Shu, Hongmei Zhao, Jing Wang, Bao Liu
JournalFrontiers in cardiovascular medicine (Front Cardiovasc Med) Vol. 9 Pg. 851603 ( 2022) ISSN: 2297-055X [Print] Switzerland
PMID35463776 (Publication Type: Journal Article)
CopyrightCopyright © 2022 Chen, Li, Shao, Lai, Gao, Wang, Song, Guo, Yu, Du, Zhu, Wang, Ma, Xu, Zhou, Liu, Shu, Zhao, Wang and Liu.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: